• RenovoRx highlighted a peer-reviewed PK/PD sub-study from its Phase III TIGeR-PaC trial in locally advanced pancreatic cancer.
• Results have already been presented via publication, pointing to more tumor-focused chemotherapy delivery with lower whole-body exposure versus standard IV dosing.
• Data also linked drug metabolism patterns to improved tumor-marker readings, supporting a potential signal of better tumor penetration.
• Enrollment in TIGeR-PaC has closed, with trial completion expected in H1 2027.
• Initial top-line results are expected in H2 2027, a key catalyst for the TAMP platform and RenovoCath commercialization strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608250830PRIMZONEFULLFEED9815224) on August 25, 2026, and is solely responsible for the information contained therein.